

# Bernard Peissel

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2028022/bernard-peissel-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

5,707  
citations

37  
h-index

73  
g-index

123  
ext. papers

6,707  
ext. citations

7.8  
avg, IF

3.72  
L-index

#	Paper	IF	Citations
122	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 371-84, 384e1-2	36.3	422
121	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 134-47	4	411
120	Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkd1 mutation. <i>Nature Genetics</i> , <b>1997</b> , 17, 179-81	36.3	381
119	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , <b>2013</b> , 45, 392-8, 398e1-2	36.3	327
118	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1347-61	27.4	286
117	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003212	6	209
116	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 680-691	36.3	190
115	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , <b>2017</b> , 49, 1767-1778	36.3	186
114	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 164-71	36.3	177
113	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. <i>Cancer Research</i> , <b>2010</b> , 70, 9742-54	10.1	147
112	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , <b>2016</b> , 53, 800-811	5.8	121
111	Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1222-30	6.7	112
110	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2240-2250	2.2	101
109	LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-diffuse leiomyomatosis. <i>American Journal of Human Genetics</i> , <b>1999</b> , 64, 62-9	11	95
108	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , <b>2016</b> , 48, 374-86	36.3	93
107	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 4442-56	5.6	91
106	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , <b>2020</b> , 52, 572-581	36.3	76

105	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 3926-39	5.6	75
104	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. <i>PLoS Biology</i> , <b>2011</b> , 9, e1001199	9.7	73
103	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R33	8.3	70
102	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 5345-55	5.6	68
101	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	65
100	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 11375	17.4	64
99	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R110	8.3	62
98	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 3304-21	5.6	62
97	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 15	8.3	58
96	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , <b>2020</b> , 52, 56-73	36.3	56
95	miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e87039	3.7	54
94	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 3416	8.3	46
93	Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. <i>PLoS ONE</i> , <b>2013</b> , 8, e57173	3.7	46
92	Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 1759-68	4.3	46
91	Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. <i>Genetics in Medicine</i> , <b>2018</b> , 20, 452-457	8.1	44
90	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 645-57	4	44
89	Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. <i>Human Mutation</i> , <b>2012</b> , 33, 1665-75	4.7	42
88	Clinical genetic testing for familial melanoma in Italy: a cooperative study. <i>Journal of the American Academy of Dermatology</i> , <b>2009</b> , 61, 775-82	4.5	39

87	Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 601-6	7.5	38
86	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 105-16	9.7	37
85	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 2966-84	5.6	36
84	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. <i>Human Mutation</i> , <b>2004</b> , 24, 100-1	4.7	36
83	MRI in the Early Detection of Breast Cancer in Women with High Genetic Risk. <i>Tumori</i> , <b>2006</b> , 92, 517-523	1.7	35
82	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , <b>2020</b> , 22, 1653-1666	8.1	34
81	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004256	6	33
80	PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 126, 825-8	4.4	32
79	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , <b>2012</b> , 33, 690-702	4.7	31
78	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 1934-46	5.6	28
77	First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. <i>BMC Cancer</i> , <b>2013</b> , 13, 46	4.8	28
76	The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 805-7	4.4	28
75	A cancer modifier role for parathyroid hormone-related protein. <i>Oncogene</i> , <b>2000</b> , 19, 5324-8	9.2	27
74	The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers. <i>Clinical Genetics</i> , <b>2014</b> , 85, 7-15	4	26
73	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0120020	3.7	26
72	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 2016-24	8.7	25
71	Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. <i>Familial Cancer</i> , <b>2011</b> , 10, 521-8	3	25
70	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 64	8.3	25

69	Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 519-27	5.7	23
68	Mutational screening of the RB1 gene in Italian patients with retinoblastoma reveals 11 novel mutations. <i>Journal of Human Genetics</i> , <b>2006</b> , 51, 209-216	4.3	23
67	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , <b>2020</b> , 80, 624-638	10.1	22
66	Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. <i>Cancer</i> , <b>2017</b> , 123, 210-218	6.4	22
65	SNPs in ultraconserved elements and familial breast cancer risk. <i>Carcinogenesis</i> , <b>2009</b> , 30, 544-5; author reply 546	4.6	22
64	Adherence to Mediterranean Diet and Metabolic Syndrome in BRCA Mutation Carriers. <i>Integrative Cancer Therapies</i> , <b>2018</b> , 17, 153-160	3	21
63	PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo. <i>Genetics in Medicine</i> , <b>2014</b> , 16, 688-94	8.1	21
62	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 308-16	4	20
61	Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 124, 251-8	4.4	19
60	Loss of tyrosinase activity confers increased skin tumor susceptibility in mice. <i>Oncogene</i> , <b>2004</b> , 23, 4130-5.2	5.2	18
59	Characterization of an Italian founder mutation in the RING-finger domain of BRCA1. <i>PLoS ONE</i> , <b>2014</b> , 9, e86924	3.7	18
58	Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 32, 65-71	3.9	18
57	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1680-91	4	17
56	Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis. <i>Annals of Human Genetics</i> , <b>2008</b> , 72, 310-8	2.2	17
55	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 61	8.3	16
54	Exploring the link between MORF4L1 and risk of breast cancer. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R40	8.3	16
53	Single base pair deletions in exons 39 and 42 of the COL4A5 gene in Alport syndrome. <i>Human Molecular Genetics</i> , <b>1994</b> , 3, 201-2	5.6	16
52	A novel frameshift deletion in type IV collagen alpha 5 gene in a juvenile-type Alport syndrome patient: an adenine deletion (2940/2943 del A) in exon 34 of COL4A5. <i>Human Mutation</i> , <b>1994</b> , 3, 386-90	4.7	16

51	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , <b>2016</b> , 141, 386-401	4.9	15
50	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 161, 117-134	4.4	15
49	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. <i>Human Genetics</i> , <b>2011</b> , 130, 685-99	6.3	15
48	Cyclin D1 expression analysis in familial breast cancers may discriminate BRCA1 from BRCA2-linked cases. <i>Modern Pathology</i> , <b>2008</b> , 21, 1262-70	9.8	15
47	A Dietary Intervention to Lower Serum Levels of IGF-I in Mutation Carriers. <i>Cancers</i> , <b>2018</b> , 10,	6.6	14
46	The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. <i>Journal of Medical Genetics</i> , <b>2011</b> , 48, 703-4	5.8	13
45	Linkage disequilibrium and haplotype mapping of a skin cancer susceptibility locus in outbred mice. <i>Mammalian Genome</i> , <b>2000</b> , 11, 979-81	3.2	13
44	Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. <i>Familial Cancer</i> , <b>2015</b> , 14, 117-28	3	12
43	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 38	7.8	12
42	An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 974-7	8.7	12
41	Mapping of melanoma modifier loci in RET transgenic mice. <i>Japanese Journal of Cancer Research</i> , <b>2000</b> , 91, 1142-7		12
40	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6034-46	5.6	11
39	Evidence for a link between TNFRSF11A and risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 129, 947-54	4.4	11
38	Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 130, 207-15	4.4	11
37	Linkage analysis for the diagnosis of autosomal dominant polycystic kidney disease, and for the determination of genetic heterogeneity in Italian families. <i>Clinical Genetics</i> , <b>1991</b> , 40, 287-97	4	11
36	Constitutional de novo deletion of the FBXW7 gene in a patient with focal segmental glomerulosclerosis and multiple primitive tumors. <i>Scientific Reports</i> , <b>2015</b> , 5, 15454	4.9	10
35	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 855-60	4.4	10
34	Constitutive Promoter Hypermethylation Can Be a Predisposing Event in Isolated Early-Onset Breast Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	10

33	Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. <i>Clinical Breast Cancer</i> , <b>2021</b> , 21, e168-e176	3	9
32	Sequencing analysis of SLX4/FANCP gene in Italian familial breast cancer cases. <i>PLoS ONE</i> , <b>2012</b> , 7, e31038	3.7	9
31	Prenatal diagnosis of autosomal dominant polycystic kidney disease using flanking DNA markers and the polymerase chain reaction. <i>Prenatal Diagnosis</i> , <b>1992</b> , 12, 513-24	3.2	9
30	A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. <i>BMC Medical Genetics</i> , <b>2014</b> , 15, 59	2.1	8
29	X chromosome inactivation pattern in BRCA gene mutation carriers. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1136-41	7.5	8
28	Two novel mutations affecting splicing in the IRF6 gene associated with van der Woude syndrome. <i>Journal of Craniofacial Surgery</i> , <b>2010</b> , 21, 1654-6	1.2	8
27	Use of intercross outbred mice and single nucleotide polymorphisms to map skin cancer modifier loci. <i>Mammalian Genome</i> , <b>2001</b> , 12, 291-4	3.2	8
26	The Spectrum of Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
25	An unusual BRCA2 allele carrying two splice site mutations. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1143-4	10.3	7
24	Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration. <i>Oncogene</i> , <b>2003</b> , 22, 7711-5	9.2	7
23	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158801	3.7	7
22	Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?. <i>Psycho-Oncology</i> , <b>2019</b> , 28, 1871-1878	3.9	6
21	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1356-61	8.7	6
20	Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171663	3.7	6
19	Analysis of and Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
18	Prenatal testing in a fetus at risk for autosomal dominant polycystic kidney disease and autosomal recessive junctional epidermolysis bullosa with pyloric atresia. <i>American Journal of Medical Genetics Part A</i> , <b>1993</b> , 47, 1225-30		5
17	Analysis of Italian Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
16	Inhibition of both skin and lung tumorigenesis by Car-R mouse-derived cancer modifier loci. <i>International Journal of Cancer</i> , <b>2002</b> , 97, 580-3	7.5	4

15	Gene linkage analysis and DNA based detection of autosomal dominant polycystic kidney disease (ADPKD) in a newborn infant. Case report. <i>Journal of Perinatal Medicine</i> , <b>1995</b> , 23, 205-12	2.7	4
14	A targeted approach to genetic counseling in breast cancer patients: the experience of an Italian local project. <i>Tumori</i> , <b>2016</b> , 102, 45-50	1.7	3
13	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
12	Cardio-Oncology: The Carney Complex Type I. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1921-1923	15.1	2
11	Is there a Specific Magnetic Resonance Phenotype Characteristic of Hereditary Breast Cancer?. <i>Tumori</i> , <b>2010</b> , 96, 363-384	1.7	2
10	Re: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 752-3; author reply 753-4	9.7	2
9	Rapid DNA-based prenatal diagnosis of autosomal dominant polycystic kidney disease. <i>JAMA Pediatrics</i> , <b>1994</b> , 148, 1101-2		2
8	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2
7	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
6	BRCA1/2 Variants and Metabolic Factors: Results From a Cohort of Italian Female Carriers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
5	Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition. <i>Cancer Genetics</i> , <b>2018</b> , 221, 38-45	2.3	1
4	Clinical applications of genetic linkage analysis for the molecular diagnostics of ADPKD, using DNA markers linked to the PKD1 and PKD2 genes. <i>Contributions To Nephrology</i> , <b>1995</b> , 115, 88-92	1.6	1
3	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , <b>2021</b> , 23, 86	8.3	1
2	The Impact of Mediterranean Dietary Intervention on Metabolic and Hormonal Parameters According to Variant Type.. <i>Frontiers in Genetics</i> , <b>2022</b> , 13, 820878	4.5	0
1	Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 857515	5.3	0